Enzyme kinetics for creatine kinase (CK), CK-MB, aspartate aminotransferase (AST), and lactate dehydrogenase (LD) in serum were followed in 14 patients who had suffered acute myocardial infarction and who were given intracoronary streptokinase shortly (mean 4.9 h, SD 2.6 h) after onset of symptoms. In the 10 patients for whom thrombolysis was successful, CK activity peaked earlier (12.8 vs 21.6 h) and at higher values (3548 vs 2436 U/L) than in the four patients for whom the treatment was unsuccessful. The mean maximum rate of increase in CK was threefold greater in the former group (574 vs 169 U/L per hour), but the total amount of CK released into the circulation and the fractional disappearance rates were similar for both groups. The profiles for AST and Extensive ischemic injury to the myocardium is a major cause of mortality in patients who have suffered acute myocardial infarction. Because the prognosis after infarction appears to be related to infarct size and to remaining ventricular function (1), various methods for reducing the extent and severity of myocardial damage have been tried, including attempts to decrease myocardial oxygen demand, increase oxygen supply by emergency bypass surgery, and (most recently) attain reperfusion (i.e., patency) of the occluded artery by infusing thrombolytic agents such as streptokinase or urokinase. Recent coronary angiographic evidence has shown that nearly 90% of patients with acute transmural infarction who were evaluated within 4 h of the onset of symptoms had a total occlusion of the infarctrelated vessel (2). Salvage of the isehemic myocardium depends critically on the duration of coronary artery occlusion, so early nonsurgical reperfusion by intracoronary infusion of streptokinase to promptly restore blood flow Results of recent randomized trials for intravenous infusion of streptokinase have suggested that such therapy significantly decreases mortality (7); this is less invasive, less expensive, and easier to perform than intracoronary administration. Unlike intracoronary infusion procedures, however, evidence for reperfusion after intravenous administration of the lytic agent cannot be based on coronary angiography, and assessment of myocardial reperfusion by noninvasive techniques is necessary. In anticipation of a need for such an indicator, we followed the activities of some serum enzymes in 14 patients who were given intracoronary streptokinase, to see whether the early peak in enzyme activity after thrombolytic therapy could serve as an indicator of the successof thrombolysis.
aspartate amiriotransferase lactate dehydrogenase . isoenzymes monitoring therapy Extensive ischemic injury to the myocardium is a major cause of mortality in patients who have suffered acute myocardial infarction. Because the prognosis after infarction appears to be related to infarct size and to remaining ventricular function (1), various methods for reducing the extent and severity of myocardial damage have been tried, including attempts to decrease myocardial oxygen demand, increase oxygen supply by emergency bypass surgery, and (most recently) attain reperfusion (i.e., patency) of the occluded artery by infusing thrombolytic agents such as streptokinase or urokinase. Recent coronary angiographic evidence has shown that nearly 90% of patients with acute transmural infarction who were evaluated within 4 h of the onset of symptoms had a total occlusion of the infarctrelated vessel (2). Salvage of the isehemic myocardium depends critically on the duration of coronary artery occlusion, so early nonsurgical reperfusion by intracoronary infusion of streptokinase to promptly restore blood flow reportedly (3-6) results in improvement of left ventricular function, a rapid decline of elevated ST segments in the electrocardiogram, relief of pain, and a rapid release of creatine kinase (CK). In these studies successful reperfusion was documented by angiography.
Departmentsof Pathology'and Medicine,2 University ofRochester Medical Center, Rochester,NY 14642. Results of recent randomized trials for intravenous infusion of streptokinase have suggested that such therapy significantly decreases mortality (7) ; this is less invasive, less expensive, and easier to perform than intracoronary administration. Unlike intracoronary infusion procedures, however, evidence for reperfusion after intravenous administration of the lytic agent cannot be based on coronary angiography, and assessment of myocardial reperfusion by noninvasive techniques is necessary. In anticipation of a need for such an indicator, we followed the activities of some serum enzymes in 14 patients who were given intracoronary streptokinase, to see whether the early peak in enzyme activity after thrombolytic therapy could serve as an indicator of the successof thrombolysis.
Patients and Methods
Patients who were evaluated and agreed to participate in the study had to fulfill the following criteria: streptokinase therapy begun within 8 h of onset of chest pain; clinical and electrocardiographic evidence of acute transmural myocardial infarction; angiographic evidence of thrombotic occlusion of a major coronary artery or a major branch of one; and no substantial contraindication of lytic therapy such as recent major surgery or cerebral vascular accident, severe uncontrolled hypertension, or significant gastrointestinal bleeding.
Once informed consent was obtained, the patients were taken to the cardiac catheterizationlaboratory.After an occluded artery was evident radiologically, patients were randomized to receive either the standard intracoronary dose (10 000 U bolus followed by a 4000 U/mm drip) or a low dose (1000-4000 U bolus and a 300-1000 U/mm drip) of streptokinase. Serial angiograms were done every 15 mm after this therapy was started. At the end of 45 mm, if there was no evidence of thrombolysis, low-dose failures were switched to standard-dose therapy, and the infusion was About 24 h after therapy with streptokinase, patients were returned to the catheterization laboratory for coronary angiography, to confirm continued patency of the previously occluded artery, and ventriculography, for comparison with pre-treatment studies.
CK activity in serum was assayed with a kit involving N- We calculated the rates of increase in serum CK and CK-MB activities by linear regression analysis for each patient from the linear portion of the upward slope of the timeactivity curves.
We calculated the clearance rates (fractional disappearance rates, Kd's) for CK and CK-MB for each patient from the declining slopes of the time-activity curves by linear regression analysis, using a logarithmic scale for serum CK and CK-MB activity (9).
The "integrated appearance functions" of CK and CK-MB are approximations of the total amounts of enzyme released into 1 L of serum. To calculate these functions, we used the formula of Shell et al. (10): E + Kd Edt, where E is the CK or CK-MB activity at time t after onset of symptoms and Kd is the fractional disappearance rate for CK or CK-MB.
Results
Sixteen patients met the above-mentioned criteria for intracoronary therapy with streptokinase. Two were excluded because of incomplete sample collection. Of the remaining 14 (13 men and one woman), 10 achieved reperfusion and four did not. Table 1 lists the characteristics of these 14 patients. Four of the 10 patients for whom reperfitsion was attained and one of the three patients for whom it was not had above-normal activity of serum CK at the time of admission, but for none of these did the value at the time of admission exceed threefold the upper limit of the normal reference interval. Table 1 Serum CK activities of patients in the reperfused group were highest 12.8 ± 5.3 h (mean ± SD) after the onset of symptoms-9 h earlier than the 21.6 ± 3.9 h for those patients who did not reperfuse ( Table 2 ). The reported (11) time for peak CK activity in serum of myocardial infarction patients treated conservatively is 20 to 30 h after onset of symptoms, similar to the mean of 21.6 h for those patients in this study for whom thrombolysis was not achieved. The mean peak activity of CK was significantly greater in the repei-fused group than in the nonreperfused patients (3548 vs 2536 U/L; p < 0.05). The mean maximum rate of increase of CK in the reperfused group was more than threefold that in the nonreperfused group (574 vs 169 UIL per hour; p < 0.005). Together, these two variables produced a CK curve for reperftised patients that resembled a spike rather than the gentle rise commonly seen in such curves for conservatively treated patients. Disappearance of CK activity from the circulation, however, appeared to be similar for both groups of patients, because the fractional disappearance rates (Kd's) were not statistically different (-0.029 vs -0027 h'; p < 0.6). The total amounts of CK released into the circulation as represented by the plateau values of the integrated appearance functions were also not significantly different (9979 vs 8653 U/L; p <0.5).
The data for CK-MB activity were similar to those for CK; the isoenzyme increased at a greater rate and peaked earlier in the reperfused group, but the total amounts released and the rates of elimination were not significantly different for reperfused and nonreperfused patients ( Table 2 ). Figure 1 shows representative CK and CK-MB curves for a reperfused patient and a nonreperfused patient.
The other enzymes followed the same trend as CK, NS, not significant. although LD peaked significantly (p < 0.05) later than CK, regardless of the outcome of therapy (Table 2 ). AST and LD in patients who reperfused peaked earlier than in those who did not. The latter group of patients had results that agreed with values reported (11) for conservatively treated patients (20 to 30 h and 30 to 60 h to peak, respectively).
Discussion
The effectiveness of thrombolytic therapy to limit myocardial damage by early restoration of coronary blood flow is being intensely investigated. Coronary angiography is used in selecting for intracoronary therapy with streptokinase patients who have complete coronary occlusion, and in demonstrating the success or failure of the treatment. In assessing the efficacy of intravenous administration of thrombolytic agent, Schroder et al. (12) relied also on angiographic data. If intravenous therapy with streptokinase proves to be successful, the benefit of thrombolytic therapy can be extended from the small proportion of patients currently being treated with intracoronary streptokinase at specialized centers to a much larger patient base in smaller hospitals, where facilities for coronary catherization and angiography are not routinely available. Easily accessible noninvasive indexes to reperfusion will be needed; the early peaking of CK activity could serve as such a marker.
The enzyme data obtained from the 14 patients in this study demonstrated early peaking of CK in patients for whom the treatment was successful;moreover, their rates of CK increase and their peak CK values were greater. Thus, these patients demonstrated the enzyme wash-out phenomenon, in basic agreement with experimental studies on dogs (13) and reports of intracoronary streptok.inase therapy in patients with transmural myocardial infarction (4,5).
The CK peaked later in the four patients who did not reperfuse, the mean interval being similar to that reported in the literature for patients being treated in coronary care units. Our study was not a randomized trial; all patients with transmural myocardial infarction who met the criteria specified above were given streptokinase therapy. Thus no control patients were available and we used reported values for comparison. However, the means for the reperfusion group and the nonreperfusiongroup are clearly different, 12.8 and 21.6 h, respectively.
In some conservatively treated patients, CK peaks as early as 8 h after onset of symptoms (14), which is similar to the early CK peaks in reperfused patients after streptokinase treatment. This early peaking of CK may reflect small infarcts. In such cases the values for peak CK will be much lower than those seen in patients successfully treated with streptokinase. Alternatively, the early peak may rasult from spontaneous recanalization, leading to reperfusion. Ong et al. (14) , in their series of 52 patients with transmural myocardial infarction, showed that 24 patients had early enzyme release (CK peaked at an average of 8.8 h) and an improved ventricular function. This lends further support to earlier angiographic evidence (2) that the proportionof patients with total coronary artery occlusion declined with time. Apparently, patients with earlier CK peaks are those who reperfuse, either by action of a thrombolytic agent or by spontaneous recanalization.
The mean rate of increase in serum CK in reperflised patients was higher than in those who did not reperfuse, which is consistent with the idea of a wash-out phenomenon. The fractional disappearance rate, as calculated from the monoexponential part of the decay curve according to the method of Norris et al. (9) , showed that CK was eliminated at about the same rate in both groups of patients, which agrees with other reports (15, 16) . This suggests that the different enzyme kinetics of the two groups of patients can be attributed to differences in the rates at which CK enters the circulation rather than to separate mechanisms of clearance from the circulation.
The peak values for CK were higher after successful thrombolysis, probably owing to a wash-out of enzymes after thrombolysis and reperfusion. The mean total amount of CK released into the serum (integrated appearance function) was greater among the reperfused group, but the difference is not significant (p < 0.5). This is in agreementwith reports on patients given intracoronary streptokinase (16) and patients who reperfused spontaneously (14) , but is at variance with the finding of Schwarz et al. (17) . Failure to demonstrate a differenceamong our patients could be in part because of largevariation ininfarct sizes. In studieson dogs, however, the amount of CK in serum was twice as high per gram of infarcted myocardiurn after reperfusion, as compared with values in permanent occlusion (13). Only some 15% (18, 19) of the CK activity depleted from the myocardium appears in the circulation, owing to inactivation during transport in the lymph. The increased rate of enzyme transit into the systemic circulation during a "washout" could have reduced the extent of enzyme inactivation. The ratio of the amount of CK depleted from the myocardiurn to the amount that appears in serum differs for reperfused and nonreperflised dogs (13); thus, the use of serial CK values and the formula developed by Sobel and associates (1, 10) for calculating infarct sizes forcomparisonbetween the two groups of patients is not valid. Calculation of infarct size in reperfused patients is also complicated by the possibilities that patients might have less than total coronary occlusion and that clot formation and lysis may be a dynamic process.
The kineticsof CK-MB in the circulation after treatment with streptokinase followed those of CK: the enzyme peak occurred earlier in reperfused patients than in conservatively treated patients. Nevertheless, the use of CK-MB rather than CK to monitor patients on thrombolytic therapy would be more specific because the problem of the contribution of nonmyocardial CK is minimized. Quantification of CK-MB activity, however, is analytically more demanding, so this test is not as readily available as CK.
The proffles of AST and LD are similar to those of CK. Thus, enzyme wash-out appears to be a general phenomenon for cardiac enzymes. CK, however, is the preferred enzyme marker. The release of liver AST, the result of poor hepatic perfusion after myocardial infarction, makes it a less specific marker. LD is similarly nonspecific. Furthermore, the later peaking of LD (25 h) is also a disadvantage.
Our data suggest that the early peaking of enzymes in reperfused patients may be sufficiently distinct from that of nonreperfused patients that it can be used as a marker for thrombolysis. In intravenous thrombolytic therapy,a similar early enzyme peak could serve as a noninvasive alternative to post-treatment angiography for monitoring successof therapy.
